Bristol-Myers Squibb Company
Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.V integrin inhibitors
Last updated:
Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to .alpha.v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
7 Nov 2017
Issue date:
25 May 2021